More than 20 billion dollars worth of biopharmaceuticals are scheduled to go off-patent by 2006. Given the strong political impetus and the development of technological tools that can answer the questions regulatory authorities may raise, it is inevitable that the FDA and EMEA will allow biogeneric or biosimilar products. Even with all the regulato
Buy this ebook and get 1 more FREE!
Language English ● Format PDF ● Pages 584 ● ISBN 9781420037937 ● Publisher CRC Press ● Published 2002 ● Downloadable 3 times ● Currency EUR ● ID 5697838 ● Copy protection Adobe DRM
Requires a DRM capable ebook reader